REGENXBIO appoints Dr. Jean Bennett and George Migausky to Board; Luke Beshar resigns

REGENXBIO Inc.

Luke M. Beshar resigned from REGENXBIO Board effective September 3, 2021.
Dr. Jean Bennett (gene therapy pioneer, co-founder of Spark Therapeutics) elected Class II director.
George Migausky (former CFO of Dyax) elected Class III director and Audit Committee member.
Each new director received option for 20,000 shares at $34.98, plus annual retainer.
Dr. Bennett will serve on Nominating and Corp Gov Committee; Mr. Migausky on Audit Committee.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Luke M. Beshar

Director

RGNX · REGENXBIO Inc.

Effective: 2021-09-03
Filed: September 7, 2021, 7:59 PM ET

On September 3, 2021, Luke M. Beshar notified REGENXBIO Inc. (the “Company”) of his resignation from the Board of Directors of the Company (the “Board”), effective immediately.

Appointed

Jean Bennett

Class II director

RGNX · REGENXBIO Inc.

Effective: 2021-09-03
Filed: September 7, 2021, 7:59 PM ET

On September 3, 2021, the Board, based upon the recommendation of the Nominating and Corporate Governance Committee, elected Jean Bennett, M.D., Ph.D., as a Class II director of the Company and a member of the Nominating and Corporate Governance Committee, effective immediately.

Appointed

George V. Migausky

Class III director

RGNX · REGENXBIO Inc.

Effective: 2021-09-03
Filed: September 7, 2021, 7:59 PM ET

On September 3, 2021, the Board, based upon the recommendation of the Nominating and Corporate Governance Committee, elected George V. Migausky as a Class III director of the Company and a member of the Audit Committee, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Luke M. Beshar resigned as Director at REGENXBIO Inc..

Action: resigned
Role: Director

Exact text from the filing

On September 3, 2021, Luke M. Beshar notified REGENXBIO Inc. (the “Company”) of his resignation from the Board of Directors of the Company (the “Board”), effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jean Bennett was elected as Class II director at REGENXBIO Inc..

Action: elected
Role: Class II director

Exact text from the filing

On September 3, 2021, the Board, based upon the recommendation of the Nominating and Corporate Governance Committee, elected Jean Bennett, M.D., Ph.D., as a Class II director of the Company and a member of the Nominating and Corporate Governance Committee, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

George V. Migausky was elected as Class III director at REGENXBIO Inc..

Action: elected
Role: Class III director

Exact text from the filing

On September 3, 2021, the Board, based upon the recommendation of the Nominating and Corporate Governance Committee, elected George V. Migausky as a Class III director of the Company and a member of the Audit Committee, effective immediately.

View on SEC.gov

REGENXBIO Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-265999

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.